Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Manage your formulary budget
|Abstract:||The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.|
|Inventor(s):||Batchelor; Kenneth William (Chapel Hill, NC), Frye; Stephen Vernon (Durham, NC), Dorsey, Jr.; George F. (Raleigh, NC), Mook, Jr.; Robert A. (Chapel Hill, NC)|
|Assignee:||Glaxo Wellcome Inc. (Research Triangle Park, NC)|
Patent Claim Types:|
see list of patent claims
Field: Not categorized
Back Citations: 86th percentile
Forward Citations: 6th percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||494||► subscribe|
|African Regional IP Organization (ARIPO)||9400669||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.